- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
News
Podcast
PODCAST: From Infection to Innovation - The Turn Therapeutics Story
Author(s):
Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.
In this episode of The Cutaneous Connection, Bradley Burnam, the founder and CEO of Turn Therapeutics, discusses his journey in the pharmaceutical landscape: from his battle with an aggressive antimicrobial resistant infection to the beginnings of Turn, and to the current state of Hexagen technology and its potential in eczema, onychomycosis, and more.
Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at DTEditor@mmhgroup.com.
Related Videos
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
Pipeline Updates on the Horizon From Arcutis Biotherapeutics
New Systemic Therapies for Pediatric Atopic Dermatitis: Dupilumab and IL-13 Inhibitors
New Nonsteroid Topical Treatments for Pediatric Atopic Dermatitis: Topical Tapinarof
The Importance of Community in Health Care
Christophe Piketty, MD, PhD: The Role of Nemolizumab in Addressing Unmet Needs of Patients With AD and PN
How Mindy Haws, MD, Empowers Women in Aesthetic Medicine
Christophe Piketty, MD, PhD: Nemolizumab's Unique Mechanism of Action and Next Steps Globally
Independent Pharmacy Overcomes Crisis with Community and Telehealth Help
Related Content
